Financial Results Summary

Quarterly Performance (₹ in lakhs):

  • Quarter ended September 30, 2026: Net loss of ₹240.01 lakh
  • Quarter ended June 30, 2026: Net loss of ₹241.07 lakh
  • Quarter ended September 30, 2025: Net profit of ₹5.52 lakh

Half-Yearly Performance (₹ in lakhs):

  • Half year ended September 30, 2026: Net loss of ₹481.08 lakh
  • Half year ended September 30, 2025: Net profit of ₹13.20 lakh
  • Full year ended March 31, 2026: Net loss of ₹945.27 lakh

Revenue Breakdown:

  • Revenue from Operations: ₹0.00 lakh for all periods presented
  • Other Income: ₹11.22 lakh (Q2 FY26), ₹11.10 lakh (Q1 FY26), ₹11.27 lakh (Q2 FY25)
  • Total Revenue: ₹11.22 lakh (Q2 FY26), ₹11.10 lakh (Q1 FY26), ₹11.27 lakh (Q2 FY25)

Expense Analysis (₹ in lakhs):

  • Employees Benefits Expense: ₹0.75 lakh (consistent across all quarters)
  • Finance Costs: ₹0.00 lakh
  • Depreciation and Amortization: ₹0.00 lakh
  • Premium on Debenture Redemption written off: ₹249.14 lakh (Q2 FY26), ₹246.43 lakh (Q1 FY26)
  • Other Expenses: ₹1.34 lakh (Q2 FY26), ₹4.99 lakh (Q1 FY26), ₹5.00 lakh (Q2 FY25)

Key Metrics:

  • Earnings Per Share (₹): (12.00) basic and diluted (Q2 FY26), (12.05) (Q1 FY26), 0.28 (Q2 FY25)
  • Paid-up Equity Share Capital: ₹200.00 lakh (unchanged across all periods)
  • Other Equity: Negative balance reflecting accumulated losses

Balance Sheet Position (as at September 30, 2026)

  • Total Assets: ₹2,057.73 lakh (unaudited)
  • Total Liabilities: ₹2,057.73 lakh (unaudited)
  • Cash and Cash Equivalents: ₹1.28 lakh (down from ₹4.55 lakh as at March 31, 2026)

Cash Flow Statement

  • Net cash from operating activities: Negative ₹3.27 lakh (half year ended September 30, 2026)
  • Net decrease in cash: ₹3.27 lakh for the period
  • Cash opening balance: ₹4.55 lakh
  • Cash closing balance: ₹1.28 lakh

Governance and Approval Process

  • Financial results reviewed by Audit Committee and approved by Board of Directors
  • Board meeting held on November 13, 2026, from 5:00 PM to 5:30 PM
  • Independent auditor's review report issued by M.D. Pandya & Associates (FRN: 107325W) with unmodified conclusion
  • Results available on company website: www.gaekwarmills.in